American Stock Exchange Lists Common Stock of RegeneRx Biopharmaceuticals, Inc. NEW YORK, March 28 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) today listed the common stock of RegeneRx Biopharmaceuticals, Inc. under the ticker symbol RGN. RegeneRx's primary business focus is the commercialization of its proprietary product, Thymosin Beta 4 ("T Beta 4"), a 43 amino acid peptide and principal component of the company's technology platform. The company is concentrating its efforts on developing T Beta 4 for various therapeutic uses such as the treatment of injured tissue and organs and to accelerate the healing of chronic wounds caused by disease, abrasion, or other pathology. To date, the Food and Drug Administration has cleared the company for three Phase II dermal wound healing clinical trials. "We are very pleased to welcome RegeneRx Biopharmaceuticals to the American Stock Exchange," said John McGonegal, senior vice president of the Amex Equities Group. "In listing at the Amex, we will be able to offer RegeneRx the value-added services that a growing company needs to succeed in today's competitive market." The specialist in RegeneRx Biopharmaceuticals will be Cohen Specialists. For further information on RGN and other Amex-listed companies, please visit http://www.amex.com/. The American Stock Exchange(R) (Amex(R)) is the only primary exchange that offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRS(SM). In addition to its role as a national equities market, the Amex is the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Leading the industry in ETF listings, the Amex lists 155 ETFs to date. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks. For more information, please visit http://www.amex.com/. DATASOURCE: American Stock Exchange CONTACT: Mary Chung, American Stock Exchange, +1-212-306-1641, Web site: http://www.amex.com/

Copyright